C-165



Health Sciences Centre Winnipeg

In Vitro Activities of Fidaxomicin and Its Metabolite OP-1118 Against Clinical Isolates of Toxin-Positive Clostridium difficile Cultured from Diarrheal Stool Specimens in Canada: CAN-DIFF 2013 J.A. KARLOWSKY¹⁻³, S. VASHISHT², G. GOLDING^{2,4}, H. ADAM¹⁻³, T. KOSOWAN^{2,4}, M. BAXTER^{2,3}, N. LAING^{2,3}, D.J. HOBAN¹⁻³, G.G. ZHANEL^{2,3}, and the CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE (CARA)

DIAGNOSTIC SERVICES SERVICES DIAGNOSTIC MANITOBA MANITOBA

REVISED ABSTRACT

Background: Clinical microbiology laboratories do not routinely culture C. difficile (CD) toxin-positive (TP) stool specimens or perform antimicrobial susceptibility testing (AST) on these isolates. As the epidemiology, susceptibility, and pathogenicity of TP-CD evolves, periodic surveillance for antimicrobial resistance and ribotypes may be useful. The current study assessed the in vitro activities of 6 routinely tested anti-anaerobic agents and the new, oral, narrow-spectrum macrocyclic antimicrobial, fidaxomicin, and its active metabolite, OP-1118, against TP-CD isolates collected in Canada in 2013.

Methods: Isolates of CD (n = 379) were cultured on *Clostridium difficile* Moxalactam Norfloxacin (CDMN) agar from TP stool specimens. Each isolate's identity was confirmed by Gram stain, typical odor, latex agglutination or a positive L-proline aminopeptidase activity test, and chartreuse fluorescence under UV light. Antimicrobial susceptibility testing was performed using the agar dilution method recommended by CLSI (M11-A8, 2012). Genotyping was performed by PCR ribotyping.

Results: All CD isolates tested were susceptible to metronidazole and amoxicillinclavulanate. Isolate percent susceptibilities were 9.5, 9.8, and 63.6%, respectively, for clindamycin, ceftriaxone, and moxifloxacin. MIC ranges (µg/mL) were ≤0.015-1 for fidaxomicin, ≤0.06-32 for OP-1118, and 0.5-4 for vancomycin. A significant difference in % susceptibility for ribotype 027 isolates (n = 22) compared with non-ribotype 027 isolates (n = 92) was only identified for moxifloxacin (P<0.001; 0% susceptible for ribotype 027) isolates versus 78% susceptible for non-ribotype 027 isolates). Fidaxomicin and OP-1118 had MIC₅₀s and MIC₉₀s one doubling-dilution higher for ribotype 027 isolates than for nonribotype 027 isolates.

Conclusion: Fidaxomicin and its active metabolite, OP-1118, demonstrated potent in vitro activity against TP-CD, including ribotype 027 isolates.

BACKGROUND

Clostridium difficile is the most frequently identified infectious cause of nosocomial diarrhea, occurring primarily in patients previously receiving antimicrobial agents. Antimicrobial susceptibility testing is rarely performed for C. difficile because of its complexity, clinical significance, and cost. Management of patients with C. difficile infection (CDI) includes withdrawal of the predisposing antimicrobial agent, if possible, and empiric therapy most commonly with either metronidazole or oral vancomycin. Recent publications have reported an increasing risk of treatment failure and CDI recurrence for patients treated with metronidazole (1-4) and have discouraged the use of vancomycin to treat CDI in hospitals to minimize the risk of vancomycin resistance in enterococci and staphylococci (5). As the adequacy of metronidazole and vancomycin as empiric therapies may be suspect and the epidemiology, susceptibility, and pathogenesis of C. difficile evolves, routine surveillance of clinical isolates to determine their in vitro susceptibility profiles, and studies determining the activities of newer agents such as fidaxomicin and OP-1118, the active metabolite of fidaxomicin, as well as other investigational agents is warranted.

REFERENCES

- Musher DM, et al. 2005. Clin Infect Dis 40:1586-90.
- Pepin J, et al. 2005. Clin Infect Dis 40:1591-7.
- McDonald LC, et al. 2006. Emerg Infect Dis 12:409-15. 8. Clinical and Laboratory Standards Institute. 2014. M100-S24
- 4. Johnson S, et al. 2014 Clin Infect Dis 59:345-54.
- 5. HICPAC. 1995. Infect Control Hosp Epidemiol 16:105-13.
- 6. National Committee for Clinical Laboratory Standards. 2002. M35-A.
- 7. Clinical and Laboratory Standards Institute. 2012. M11-A8.
- 9. Warren N, et al. 2014. Manuscript in preparation.

Table 1. Antimicrobial	susceptibility	testing r	esults for 3	79 toxin-po	sitive isol	ates of <i>C.</i>	difficile	-	Table 2. Distribution of M	ICs for ant	imicrobi	als test	ed agains	st 379 t	oxin-p	ositive	e isolat	tes of (<mark>C. d</mark>
		MIC (µg/ml)		МІС	C interpret	ation					Num	ber of isc	olates fo	or whi	ch the	antimi	icrobia	l ag
Antimicrobial agent	Range	Mode	MIC ₅₀	MIC ₉₀	% S	% I	% R		Antimicrobial agent	0.015	0.03	0.06	0.125	0.25	0.5	1	2	4	8
Fidaxomicin	≤0.015-1	0.5	0.25	0.5	NA	NA	NA		Fidaxomicin	6 ^a	5	11	83	94	163	17			
OP-1118	≤0.06-32	8	8	16	NA	NA	NA		OP-1118			8 ^a		1	3	17	56	102	11
Metronidazole	0.25-8	0.5	0.5	2	100	0	0		Metronidazole					29	184	66	91	6	3
Vancomycin	0.5-4	1	1	1	NA	NA	NA		Vancomycin						61	288	24	6	
Amoxicillin-clavulanate	≤0.25-8	1	1	2	100	0	0		Amoxicillin-clavulanate					10 ^a	10	211	144	3	1
Clindamycin	≤0.12->64	4	4	16	9.5	50.1	40.4		Clindamycin				7 ^a	3	1	1	24	190	11
Moxifloxacin	≤0.25->32	1	2	>32	63.6	1.1	35.3		Moxifloxacin					6 ^a	4	134	97	4	2
Ceftriaxone	≤0.5->128	32	32	64	9.8	56.7	33.5		Ceftriaxone						8 ª	1		1	1

NA – MIC interpretive breakpoints not available; S: susceptible, I: intermediate, R: resistan

Table 3. PCR ribotyping analysis for 114 isolates

Ribotype	n (% of all isolates)
027	22 (19.3%)
014	10 (8.8%)
106	7 (6.1%)
020	6 (5.3%)
ns37	5 (4.4%)
002	4 (3.5%)
017	4 (3.5%)
087	4 (3.5%)
056	3 (2.6%)
072	3 (2.6%)
ns25	3 (2.6%)
015	2 (1.8%)
046	2 (1.8%)
075	2 (1.8%)
076	2 (1.8%)
ns18	2 (1.8%)
ns28	2 (1.8%)
ns36	2 (1.8%)
Singular ribotypes	29 (25.4%)

Diagnostic Services Manitoba¹, University of Manitoba², Canadian Antimicrobial Resistance Alliance (CARA)³, and National Microbiology Laboratory (NML), Public Health Agency of Canada⁴, Winnipeg, Manitoba, Canada

RESULTS

Isolate count shown for lowest the dilution tested; some MICs may be lower than the lowest dilution tested

^b 35/38 isolate MICs for clindamycin were >64 µg/ml

^c 64/83 isolate MICs for moxifloxacin were >32 µg/ml

^d 16/127 isolate MICs for cetriaxone were >128 µg/ml.

	MIC (µg/ml)								
Antimicrobial agent	Ribotype	Range	Mode	MIC ₅₀	MIC ₉₀	% Susceptible	% Inte		
Fidaxomicin	027	0.25-1	0.5	0.5	1	NA	1		
	014	0.12-0.5	0.12	0.12	0.5	NA	1		
	Non-027 Ribotypes	0.03-1	0.5	0.25	0.5	NA	1		
OP-1118	027	8-16	8	8	16	NA	1		
	014	1-8	2/4	2	4	NA	1		
	Non-027 Ribotypes	0.5-16	4	4	8	NA	1		
Metronidazole	027	1-2	2	2	2	100			
	014	0.5-1	0.5/1	0.5	1	100			
	Non-027 Ribotypes	0.25-2	0.5	0.5	2	100			
Vancomycin	027	0.5-4	1	1	1	NA	1		
	014	0.5-1	1	1	1	NA	1		
	Non-027 Ribotypes	0.5-4	1	1	1	NA	1		
Amoxicillin-	027	0.5-4	2	2	2	100			
clavulanate	014	0.5-1	1	1	2	100			
	Non-027 Ribotypes	0.5-4	1	1	2	100			
Clindamycin	027	2->64	4	4	8	4.6	6		
	014	4	4	4	4	0	1		
	Non-027 Ribotypes	1->64	4	4	64	8.5	5		
Moxifloxacin	027	16->32	>32	>32	>32	0			
	014	1-2	2	2	2	100			
	Non-027 Ribotypes	1->32	1	2	16	78	2		
Ceftriaxone	027	32->64	64	64	64	0	ç		
	014	16-64	32	32	32	20			
	Non-027 Ribotypes	16->64	32	32	64	6.1	7		

Table 4. Antimicrobial susceptibility testing results for 114 toxin-positive isolates of Clostridium difficile stratified according to PCR ribotype

54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 6-9, 2014

difficile ent MIC (µg/ml) was: 16 32 ≥64 15 76 1 38^b 49 83° 26 215 127^d

pretation	
nediate	% Resistant
A	NA
)	0
	0
	0
A	NA
A	NA
Ą	NA
	0
)	0
)	0
.6	31.8
0	0
.8	31.7
)	100
	0
5	19.5
1	90.9
0	10
2	20.7

CANADIAN ANTIMICROBIAL CARA

www.can-r.ca



Dr. James Karlowsky Dept of Clinical Microbiology St. Boniface Hospital 409 Tache Avenue, L4025-10 Winnipeg, MB, R2H 2A6 Email: jkarlowsky@dsmanitoba.ca

METHODS

Bacterial isolates studied. 379 isolates of C. difficile were cultured on Clostridium difficile Moxalactam Norfloxacin (CDMN) Selective Supplement agar (Oxoid Canada, Nepean, ON, Canada) from TP stool specimens (following an ethanol shock step) submitted by 8 hospital clinical microbiology laboratories across Canada to the Winnipeg Health Sciences Centre. Each isolate's identity was confirmed by Gram stain, typical odor, latex agglutination (Microgen Bioproducts Ltd., Surrey, UK) or a positive L-proline aminopeptidase activity test, and chartreuse fluorescence under UV light (6).

Antimicrobial susceptibility testing. Antimicrobial susceptibility testing for fidaxomicin, OP-1118, and 6 additional agents was performed using the agar dilution method recommended by CLSI (7). Fidaxomicin and OP-1118 were supplied by Cubist Pharmaceuticals, Inc.; the solvent for both compounds was DMSO; water was used as the diluent. C. difficile ATCC 700057 was used as the control strain; the reference MIC range for this strain was 0.03-0.25 µg/ml for fidaxomicin. In vitro susceptibility testing interpretive criteria for fidaxomicin have not been determined; CLSI breakpoints were used to interpret MICs for the other antimicrobial agents tested (8).

PCR Ribotyping. 114 isolates were ribotyped at the National Microbiology Laboratory-Public Health Agency of Canada, using an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for C. difficile (9).

CONCLUSIONS

- All TP C. difficile isolates tested were susceptible to metronidazole and amoxicillinclavulanate; 9.5, 9.8, and 63.6% of isolates were susceptible to clindamycin, ceftriaxone, and moxifloxacin, respectively. The $MIC_{90}s$ for fidaxomicin and vancomycin were 0.5 and 1 µg/ml, respectively (Table 1).
- Against TP clinical isolates of *C. difficile*, the potencies of the 8 agents tested, based upon $MIC_{00}s$, were: fidaxomicin > vancomycin > metronidazole = amoxicillin-clavulanate >> OP-1118 = clindamycin >> ceftriaxone = moxifloxacin (Table 1)
- The highest MIC reported for fidaxomicin was 1 µg/ml compared with 4 µg/ml for vancomycin and 8 µg/ml for amoxicillin-clavulanate and metronidazole (Table 2).
- There was tremendous ribotype diversity among the isolates of *C. difficile* tested (Table 3).
- Ribotype 027 was the most frequent identified ribotype, accounting for approximately 20% of isolates; all ribotype 027 isolates were resistant to moxifloxacin (Table 3).
- Ribotype 014 isolates were more susceptible to moxifloxacin, clindamycin, and ceftriaxone than were other ribotypes (Table 4).
- Fidaxomicin demonstrated greater *in vitro* potency than vancomycin, metronidazole, and amoxicillin-clavulanate based upon MIC₉₀s and had a lower maximum MIC (1 µg/ml) than did the three other agents (4-8 µg/ml)
- A significant difference in % susceptibility for ribotype 027 isolates (n = 22) compared with non-ribotype 027 isolates (n = 92) was only identified for moxifloxacin (P < 0.001; 0%) susceptible for ribotype 027 isolates versus 78% susceptible for non-ribotype 027 isolates).
- Fidaxomicin and OP-1118 had MIC_{50} s and MIC_{90} s one doubling-dilution higher for ribotype 027 isolates than for non-ribotype 027 isolates.
- Fidaxomicin and its active metabolite, OP-1118, demonstrated potent in vitro activity against TP-CD, including ribotype 027 isolates.

ACKNOWLEDGEMENTS

The authors would like to thank the laboratory staff at CAN-DIFF sites for their assistance with specimen collection. The study was supported in part by the Health Sciences Centre, University of Manitoba, National Microbiology Laboratory, and Cubist Pharmaceuticals.